1st Annual BioPharma Obesity Innovation Forum

Building on the success of previous obesity panels and keynote in our Swiss events featuring many of the main players, we are pleased to introduce the 1st Annual BioPharma Obesity Innovation Forum (Sachs_BOIF). This event will take place at the Marines’ Memorial Club, San Francisco on the 11th of January 2025, a day before the 8th Annual Neuroscience Innovation Forum (Sachs_NIF). This new addition precedes the JP Morgan meeting, with the Virtual Week scheduled on the 21st – 23rd of January, offering relevant attendees the opportunity to register for both events.

We are witnessing a global obesity pandemic. By some estimates, a quarter of the world’s population will be obese by 2025. The obesity/weight loss drug market is the fastest-growing segment in the biopharma industry, with annual sales forecast to rise over $200 billion in the near term. Additionally, over 200 other conditions are associated with obesity. These include cardiometabolic diseases, cancer, inflammatory diseases, infertility, anxiety, depression, and kidney disease. This impacts the reimbursement case.

The comprehensive programme for the BOIF will feature over 7 hours of high-level keynotes, panel discussions, and corporate presentations covering all aspects of the bio-pharma obesity science and market, including drug development and technology, as well as highlighting investment opportunities. The sessions will be made available on demand for the virtual audience the week after the JP Morgan meeting. This forum will also set the stage for our first Obesity focused European event scheduled for the 17th – 19th of June 2025 in Leipzig. Key topics to be covered at the upcoming event include:

● Fireside Chat with Dr. Bei B. Zhang, Corporate VP & TA Head – Diabetes, Obesity & MASH, Novo Nordisk A/S
● Potential Magnitude of Market & Impact on the Healthcare System Panel
● BioPharma Dealmaking: Building the Pipeline Panel
● Personalized Approaches to Treating Obesity Panel
● Unmet Needs & NextGen Therapeutics Panel
● Obesity, Cardiovascular & Metabolic Diseases Platforms Panel
● Innovation in Digital, Tech & Dx for Obesity, Diabetes & MASH Panel
● Investor RoundtableIn-Person Meetings – 11th of January
Virtual Meetings via Online Meeting System - 21st – 23rd of January
Networking Reception – 11th of January

● Amir Zamani, Managing Director Life Sciences, Bain Capital
● Annabel Samimy, Managing Director, Biopharmaceuticals, Stifel
● Antoine Boulanger, Principal, Forbion
● Blake Salisbury, SVP Global Business Development, Innovent Biologics
● Camilla Easter, CEO, Oxford Medical Products Ltd.
● Dr. Bei B. Zhang, Corporate VP & TA Head – Diabetes, Obesity & MASH, Novo Nordisk A/S
● Daniel Swisher, CEO, NodThera, Inc.
● David Kendall, Chief Medical Officer, Zealand Pharma A/S
● David Meeker, Chair, President & CEO, Rhythm Pharmaceuticals, Inc.
● Dawn Bell, Executive Chair, Myracle Therapeutics, Inc.
● Dennis McWilliams, Venture Partner, Santè Ventures
● Dennis Purcell, Founder, Aisling Capital LLC
● Diana Saraceni, Co-Founder & General Partner, Panakès Partners SGR SpA
● Edward van Wezel, Managing Partner, BioGeneration Ventures
● Enrique Conterno, Board Member, Zealand Pharma A/S
● Erik Ingelsson, CSO, Wave Life Sciences
● Iain Dukes, Venture Partner, OrbiMed Advisors LLC
● Jay Olson, Managing Director & Senior Analyst, Oppenheimer & Co. Inc.
● Jeff Berkowitz, CEO, Real Endpoints
● John McDonald, CVP, Head of BD and M&A, Novo Nordisk A/S
● Justin Zelin, Director, Biotechnology Research Analyst, BTIG, LLC
● Kent Rogers, CEO, EveryONE Medicines Inc.​
● Lauren Shearman, Worldwide Business Development (WWBD) Search & Evaluation Team Leader , Pfizer, Inc.
● Laurent Audoly, Co-Founder & CEO, PriveBio
● Leland Gershell, Managing Director, Equity Research – Biotechnology, Oppenheimer & Co. Inc.
● Michael Davidson, CEO, NewAmsterdam Pharma B.V.
● Michael Kingston, Managing Director & Head of North America Life Sciences, Lazard Ltd.
● Neil Anderson, Senior Director, Science2Medicine iNNvest, Novo Nordisk A/S
​● Olivier Soula, Co-Founder & CEO, ADOCIA
​● Orly Mishan, Managing Director, Perceptive Advisors, LLC
● Peng Leong, Chief Business Officer & Head of Brain Aging, BioAge Labs, Inc.
​● Philip Larsen, CEO, Six Peaks Bio
● Ron Renaud, President & CEO, Kailera Therapeutics
● Sayan Bhattacharya, Executive Director, J.P. Morgan Asset Management
● Shaheen Lakhan, Chief Medical Officer, Click Therapeutics, Inc.
● Steffen-Sebastian Bolz, CSO, APHAIA Pharma AG
● Steve Dickman, CEO, CBT Advisors
● Tim Opler, Managing Director, Stifel
● Vipin K. Garg, President & CEO, Altimmune
● More TBA…

● Matthias Tschöp, CEO, Helmholtz Munich – Keynote Speaker
● Anders Bue Klein, Co-Founder & CEO, Ousia Pharma ApS
● Antoine Boulanger, Principal, Forbion
● Birgit Steckel-Hamann, Sr. Director Diabetes External Innovation & Head of Public Private Partnerships Europe, Eli Lilly and Company
● Francois Ravenelle, CEO, Inversago Pharma
● Gijs van den Brink, SVP and Global Head Cardiovascular & Metabolism, Immunology, Infectious Diseases and Ophthalmology, F. Hoffmann-La Roche Ltd.
● Josua Jordi, Co-Founder & CEO, EraCal Therapeutics Ltd.
● Marc Ditmarsch, CTO, NewAmsterdam Pharma
● Philip Larsen, CEO, Six Peaks Bio
● Rianne Ellenbroek, Principal, BioGeneration Ventures
● Victoria English, Co-Founder & Editor of Evernow Publishing Ltd, publisher, MedNous

The target audience for the BOIF forum includes buy-side and sell-side analysts from investment banks and funds, partnering executives from pharma, biotech, medtech, and digital health companies, as well as consultants and CROs working in the space. We anticipate over 200+ delegates in-person and 15+ company presentations by both established and emerging companies. This will feature a limited number of live presentations in dedicated presentation tracks, along with virtual company showcases available on demand. Recorded sessions will also be accessible on the event portal during the virtual week, beginning on the 21st of January. The conference will be held in the Pacific Standard Time (PST) zone.